The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 18, 2021
Filed:
May. 18, 2018
Applicant:
Ausvir Therapeutics Pty Ltd, Melbourne, AU;
Inventors:
Betty Jin, Victoria, AU;
Ee-Ling Seah, Victoria, AU;
Paul Arthur Jones, Victoria, AU;
Peter James Jenkins, Victoria, AU;
Henry Kenneth Windle, Victoria, AU;
Wen Yang Wu, Victoria, AU;
Assignee:
Ausvir Therapeutics Pty LTD, Melbourne, AU;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/54 (2017.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); C07K 5/113 (2006.01); C07K 7/06 (2006.01); C07K 5/093 (2006.01); C07K 5/072 (2006.01); C07D 407/14 (2006.01); C07D 309/28 (2006.01); A61K 45/06 (2006.01); A61P 31/16 (2006.01); A61K 31/351 (2006.01); A61K 39/42 (2006.01); C07K 16/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/645 (2017.08); A61K 31/351 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61K 47/549 (2017.08); A61K 47/6841 (2017.08); A61P 31/16 (2018.01); C07D 309/28 (2013.01); C07D 407/14 (2013.01); C07K 5/06104 (2013.01); C07K 5/0819 (2013.01); C07K 5/1021 (2013.01); C07K 7/06 (2013.01); C07K 16/1018 (2013.01); A61K 2039/505 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01);
Abstract
The present invention provides compounds for use in treating and/or preventing influenza. The compound comprises a first and second domain in which the first domain comprises at least one anchoring group which binds to the surface of influenza viruses and the second domain comprises at least one anionic group. The first and second domains are covalently linked. Also provided are pharmaceutically acceptable salts, solvates, prodrugs or stereoisomer of the compounds.